Insights - Novavax continues to face regulatory hurdles with their COVID vaccine, and it has been reflected in the company’s stock price. Lack of execution has outweighed … Continue Reading
PremiumInsights - Biotech (XBI) is back under $125 after a small September rally. On biotech weakness, we’re looking to buy companies on our watchlist or add to … Continue Reading
PremiumInsights - Affimed (AFMD) released Q2 2021 business update today and it was mixed. AFM13 + MD Anderson collaboration in blood cancers seems to be progressing well, with data … Continue Reading
PremiumResearch - Medicenna (MDNA) is developing a next-gen IL-2 candidate against solid tumors. The company expects to report Phase 1 biomarker data by the end of 2021, … Continue Reading
PremiumInsights - The FDA granted Pfizer and partner BioNTech full approval for their vaccine last week. Meanwhile, there were reports from Reuters that Novavax (NVAX) may face additional delays … Continue Reading
PremiumInsights - Biotech got a jolt of life after Pfizer announced the $2.26B acquisition of Trillium (TRIL), at a 204% premium to market close on Friday. The … Continue Reading
PremiumInsights - Fate Therapeutics (FATE) reported additional data for their two off-the-shelf NK cell programs after market yesterday. This was an important event because it would read-through to NK … Continue Reading
Premium
